Jakap Koo - 12 May 2025 Form 4 Insider Report for Apimeds Pharmaceuticals US, Inc. (APUS)

Role
Director
Signature
/s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact
Issuer symbol
APUS
Transactions as of
12 May 2025
Net transactions value
+$56,715
Form type
4
Filing time
14 May 2025, 17:58:18 UTC
Previous filing
08 May 2025
Next filing
20 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Koo Jakap Director C/O APIMEDS PHARMACEUTICALS US, INC., 2 EAST BROAD STREET, 2ND FLOOR, HOPEWELL /s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact 14 May 2025 0002041972

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APUS Common Stock, par value $0.01 per share Purchase $56,715 +28,500 +4.6% $1.99 643,885 12 May 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Apimeds Pharmaceuticals US, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
F2 These shares were sold in multiple transactions at prices ranging from $1.9774 to $2.2000, inclusive.